Cost-effectiveness analyses of drug eluting stents versus bare metal stents: A systematic review of the literature

被引:22
|
作者
Neyt, Mattias [1 ]
Van Brabandt, Hans [1 ]
Devriese, Stephan [1 ]
De Laet, Chris [1 ]
机构
[1] Belgian Hlth Care Knowledge Ctr KCE, B-1000 Brussels, Belgium
关键词
Drug-eluting stents; Cost-benefit analysis; Review; CORONARY STENT; FOLLOW-UP; ECONOMIC-IMPACT; BYPASS-SURGERY; RESTENOSIS; DISEASE; TRIALS; CARE; ANGIOPLASTY; OUTCOMES;
D O I
10.1016/j.healthpol.2008.11.014
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Drug eluting stents (DES) used to treat coronary lesions reduce rates of in-stent restenosis and therefore the need for repeat revascularization compared to bare metal stents (BMS). DES, however, are considerably more expensive than BMS. We evaluated whether DES are a cost-effective alternative for BMS. Methods: Reports of Health Technology Assessment agencies were assessed and a systematic review of economic evaluations comparing DES with BMS was performed. Results: Nineteen full economic evaluations were identified. Some studies indicate that DES may be cost-effective or even cost-saving in specific patients, when used for coronary lesions with a high propensity of restenosis such as long lesions, lesions in narrow vessels, or in patients with diabetes. Other studies mention DES is not cost effective at all with ICERs of more than 200,000 Canadian dollar per QALY gained. One of the main determining factors is the influence of protocol mandated angiographic follow-up in RCTs. The risk for a re-intervention using BMS ranges from 5% to 14% in registries and is much smaller than reported in RCTs (up to 30%). As a result, the absolute reduction in repeat revascularization by DES compared to BMS is smaller in real life. Moreover, using DES instead of BMS does not increase survival or decrease myocardial infarctions. The combination of (a) a higher cost (>(sic)700) for DES versus BMS; (b) no life-years gained: (c) a relatively small absolute reduction in repeat procedures; and (d) a small improvement in QoL for a short period (less than 0.15 during the first month after the re-intervention), results in unfavourable cost-effectiveness ratios. Conclusions: Although several studies conclude that DES may be cost effective in large subgroups of patients, under real-world conditions, the cost-effectiveness of DES is unfavourable in comparison with BMS. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:107 / 120
页数:14
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE METAL STENTS IN TAIWAN
    Fang, N.
    Yao, M.
    Tseng, T.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A45 - A45
  • [2] Cost-Effectiveness of Drug-Eluting Stents Versus Bare Metal Stents in Clinical Practice
    Schafer, Pascha E.
    Sacrinty, Matthew T.
    Cohen, David J.
    Kutcher, Michael A.
    Gandhi, Sanjay K.
    Santos, Renato M.
    Little, William C.
    Applegate, Robert J.
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (04): : 408 - 415
  • [3] COST-EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE METAL STENTS IN EGYPTIAN DIABETIC PATIENTS
    ElSisi, G.
    Ragab, S.
    Ashraf, R.
    Elmahdawy, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A530 - A530
  • [4] DECISION ANALYTIC MODELS USED IN ESTIMATING THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE-METAL STENTS: A SYSTEMATIC REVIEW
    Burgers, L. T.
    Redekop, W. K.
    Severens, J. L.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A588 - A588
  • [5] The cost-effectiveness of drug-eluting stents: a systematic review
    Ligthart, Suzanne
    Vlemmix, Floortje
    Dendukuri, Nandini
    Brophy, James M.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 176 (02) : 199 - 205
  • [6] Drug Eluting Versus Bare Metal Stents in Cardiac Allograft Vasculopathy: A Systematic Review of Literature
    Dasari, Tarun W.
    Hennebry, Thomas A.
    Hanna, Elias B.
    Saucedo, Jorge F.
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2011, 77 (07) : 962 - 969
  • [7] Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention
    Baschet, Louise
    Bourguignon, Sandrine
    Marque, Sebastien
    Durand-Zaleski, Isabelle
    Teiger, Emmanuel
    Wilquin, Fanny
    Levesque, Karine
    [J]. OPEN HEART, 2016, 3 (02):
  • [8] DECISION ANALYTIC MODELS USED IN ESTIMATING THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE-METAL STENTS
    Burgers, L. T.
    Redekop, W.
    Severens, J. L.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A259 - A259
  • [9] Cost-effectiveness of sirolimus-eluting stents compared with bare-metal stents
    Caroline Barranco
    [J]. Nature Clinical Practice Cardiovascular Medicine, 2005, 2 (9): : 439 - 439
  • [10] Drug-eluting stents versus bare metal stents
    Conti, CR
    [J]. CLINICAL CARDIOLOGY, 2003, 26 (11) : A31 - A32